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recurrence of Clostridium difficile-Induced colitis
following vancomycin withdrawal in mice
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Background: Recently, we found that the probiotic strain Bacillus coagulans GBI-30, 6086 (GanedenBC30) improved
indices of Clostridium difficile (C. difficile)-induced colitis in mice (Fitzpatrick et al., Gut Pathogens, 2011). Our goal was
to determine if BC30 could also prevent the recurrence of C. difficile-induced colitis in mice, following initial
treatment with vancomycin. During study days 0 through 5, mice were treated with antibiotics. On day 6, the
C. difficile strain VPI 10463 was given by oro-gastric gavage at ≈ 5x104 CFU to induce colitis. Mice were treated on
study days 6 to 10 with vancomycin (50 mg/kg) (vanco) or vehicle (saline) by gavage. On days 10 to16, mice were
dosed by gavage with saline vehicle or BC30 (2 x 109 CFU per day). Mice were monitored for mortality, weight loss
and diarrhea. On study days 14, 16 and 17, stools and colons were collected for analyzing other parameters of
colitis.
Results: The mean stool consistency score in Vehicle/C.difficile/Vanco mice increased from 0.4 (day 10) to a range
of 1.1 to 1.4 (days 14 to 17), indicating the recurrence of colitis. On days 13 through 17, the stool consistency scores
for the vancomycin/BC30 mice were significantly lower (p< 0.05) than for the vancomycin/vehicle cohort of
animals. On day 17, 88.9% of mice treated with BC30 had normal stools, while this value was 0% with vehicle
treatment (p value = 0.0004). Colonic myeloperoxidase (Units/2 cm colon) was significantly (p < 0.05) reduced from
4.3 ± 0.7 (Vehicle/C.difficile/Vanco) to 2.6 ± 0.2 (BC30/C. Difficle/Vanco). The colonic histology score and
Keratinocyte derived-chemokine level in the colon were also lower in BC30 treated mice.
Summary: In BC30-treated mice, there was evidence of better stool consistency, as well as improved biochemical
and histological indices of colitis, following initial treatment of animals with vancomycin.
Conclusion: BC30 limited the recurrence of CD-induced colitis following vancomycin withdrawal in mice.
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Clostridium difficile (C. difficile) infection (CDI) is a very
common cause of health-care associated diarrhea and
colitis [1]. Moreover, CDI is associated with significant
morbidity, as well as increased health care costs [2]. The
spectrum of C. difficile associated disease (CDAD)
ranges from mild antibiotic associated diarrhea to severe
and life threatening pseudomembranous colitis [3].
CDAD is caused by the actions of two toxins (toxin A* Correspondence: keller@ganedenbiotech.com
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reproduction in any medium, provided the orand toxin B), which are produced by pathogenic strains
of C. difficile [4,5]. Toxin A results in the activation of
three transcription factors (NF- kB, AP1 and CREB).
NF-kB (nuclear factor-kappa B) is involved in chemokine
production, and also plays a role in colonocyte apoptosis
[6,7]. AP-1 (activator protein-1) plays a role in IL-8 pro-
duction in response to stimulation of colonocytes with
toxin A [8]. CREB (Cyclic-AMP Response Binding Pro-
tein) is critical for the production of prostaglandin E2 via
inducible cyclooxygenase-2 (COX-2) [9]. This prosta-
glandin plays an important role in the fluid secretion
and diarrhea associated with CDAD.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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biotics such as vancomycin (vanco) or metronidazole
[10,11]. However, recurrence occurs in at least 20% of
patients [11]. Some clinical studies have focused on
combined treatment with vancomycin and probiotics
such as Saccharomyces boulardii for the treatment of re-
currence [12-15]. Therefore, the use of probiotics, for
prevention of recurrent disease, may be attractive as part
of the overall therapeutic strategy for CDAD [12-15].
Bacillus coagulans GBI-30, 6086 (GanedenBC30) is a
spore-forming probiotic strain that is resistant to ex-
treme temperatures and survives in the gut environment
[16]. BC30 was shown to have anti-inflammatory and
immunomodulatory effects in vitro and in vivo [17,18].
Previously, we reported that BC30 improved various
parameters of C. difficile-induced colitis in mice [18].
Additionally, BC30 prolonged the survival time in C.
difficile-infected mice [18]. While the initial research fo-
cused on primary treatment of C. diifficile, this study
reached the ability to prevent re-occurrences of C. Diffi-
cile infection following withdrawal of Vancomycin.
Recently, other investigators have described the recur-
rence of CDAD following vancomycin withdrawal in
mice [10,19]. Overall, recurrence is associated with some
evidence of disease (weight loss, diarrhea), as well as typ-
ical histological evidence of CDAD [10,19]. With know-
ledge of this previous scientific information, the goal of
our study was to determine if BC30 could prevent recur-
rence of CD-induced colitis following vancomycin with-
drawal in mice.
Results
Effects of BC30 on mouse survival and body weight, as
well as the presence of C. difficile infection and toxins
Figure 1 shows an overview of the key events associated
with the C. difficile recurrence model that we used for
this study. Cumulative survival rates in the study were:Figure 1 Study overview. The key events associated with the Clostridium
through 3, C57BL/6 mice received an antibiotic mixture of kanamycin, gen
followed by clindamycin (10 mg/kg, i.p., on day 5). On day 6, the C. difficile
induce colitis. Mice were treated on study days 6 to 10 with Vanco (50 mg
by gavage with vehicle (50% maltodextrin/saline, n=29) or BC30 (2 x 109 C
dosed with vehicle, but did not receive C. difficile, while a positive control g
monitored daily (days 6 to 17) for mortality, weight loss and stool consisten
further analyses.100% (Vehicle/No C. difficile), 87.5% (Vehicle/C. diffi-
cile/No Vanco), 100% (Vehicle/C. difficile/Vanco) and
100% (BC30/C. difficile/Vanco). No statistically signifi-
cant differences were found for mouse survival.
The incidence rates of C. difficile infection from study
days 14, 16 and 17 were: 0% (0/6, Vehicle/No C. difficile),
100% (7/7, Vehicle/C. difficile/No Vanco), 97% (28/29,
Vehicle/C. difficile/Vanco) and 89% (25/28, BC30/C. diffi-
cile/Vanco) [Figure 2A]. The percentages of toxin A/B posi-
tive stools from these study days were: 0% (Vehicle/No C.
difficile), 57% (Vehicle/C. difficile/No Vanco), 41% (Vehicle/
C. difficile/Vanco) and 64% (BC30/C. difficile/Vanco). How-
ever, the semi-quantitative determination of toxin A/B
levels (n = 6–13 per treatment group) showed increased ab-
sorbance readings (1.429 ± 0.456) from the stools of Ve-
hicle/C. difficile/Vanco treated mice, as compared to
absorbance readings (1.128 ± 0.410) from stools of BC30/C.
difficile/Vanco treated animals [Figure 2B].
The mean body weights (grams) of mice on study day 6
were: 20.7 ± 0.5 (Vehicle/No C. difficile), 21.7 ± 0.6
(Vehicle/C. difficile/No Vanco), 21.8 ± 0.3 (Vehicle/C.
difficile/Vanco) and 21.9 ± 0.3 (BC30/C. difficile/Vanco).
Of note, surviving Vehicle/C. difficile/No Vanco treated
mice did transiently lose an average of 1.1 grams between
study days 7 and 9. On study day 17, the mean body
weights (grams) of remaining mice (n = 2 to 9 per treat-
ment group) were: 20.5 ± 0.5 (Vehicle/No C. difficile),
21.5 ± 0.7 (Vehicle/C. difficile/No Vanco), 22.4 ± 0.6 (Ve-
hicle/C. difficile/Vanco) and 22.1 ± 0.5 (BC30/C. difficile/
Vanco). There were no statistically significant differences
in net body weight gains during the study (days 6 to 17).
BC30 treatment significantly improved the stool
consistency in C. difficile infected mice
Figure 3 illustrates the effects of BC30 treatment on stool
consistencies in C.difficile treated mice. The mean stool
consistency score in Vehicle/C. difficile/Vanco treated micedifficile induced colitis mouse model are shown. On study days 0
tamicin, colistin, metronidazole and Vanco in the drinking water,
strain VPI 10463 was given by oro-gastric gavage at ≈ 5x104 CFU to
/kg) or vehicle (saline) by gavage. On days 10 to 16, mice were dosed
FU per day, n=28). One negative control group of mice (n=6) was
roup (initial n of 8) received C. difficile but not Vanco. Mice were
cy. On study days 14, 16 and 17, stools and colons were collected for
Figure 2 Infection and toxin data. A) The percentages of animals positive for C. difficile in the stool were determined by ELISA on study day 14, 16
and 17. * indicates p< 0.05 vs. all other C. difficile infection groups. B) Toxin A/B levels were determined in a semi-quantitative fashion with an
appropriate ELISA kit, as described in the Methods section. The values in the graph represent absorbance readings at 450 nm. * indicates p< 0.05 vs. all
other C. difficile infection groups.
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range of 1.1 to 1.4 for days 14 to 17. This increase in stool
consistency score indicates the recurrence of colitis. In con-
trast, during this time period, there was virtually no in-
crease in the mean stool consistency score of BC30/C.
difficile/Vanco treated mice (green symbols and lines). The
stool consistency scores were significantly lower in this co-
hort of animals (p < 0.05 vs. Vehicle/C. difficile/Vanco treat-
ment) on study days 13 through 17 [Figure 3A].In Figure 3B, a significant difference (p<0.05) in the
percentage of mice with normal stools was evident in
the BC30/C. difficile/Vanco group, as compared to the
Vehicle/C. difficile/Vanco group, on days 14 to 17. On
day 17, 88.9% of mice treated with BC30 had normal
stools compared to 0% of mice with normal stools in the
Vehicle treated animals (p=0.0004 vs. Vehicle).
Stool sizes (lengths, with higher numbers indicative or
more normal stools) in mm (n = 2 to 18 per group)
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Figure 3 Stool consistency data. A) Mice were randomized on study day 6 to one of four treatment groups. All mice in the negative control
group (n=6) that did not receive C. difficile (black symbols, lines) generally had normal stools throughout the study. Stool consistency scores were
higher in the group of mice (blue symbols, bars) that were treated with Vehicle/C. difficile/No Vanco. In these animals, disease was prominently
present on days 7 to 9. For the other two experimental groups, mice received Vehicle/C. difficile/Vanco and either Vehicle (red symbols, lines) to
induce disease recurrence (study days 11 to 17), or BC30 at a dose of 2 x 109 CFU per day (green symbols, lines). * indicates p < 0.05 vs. BC30/C.
difficile/Vanco treatment group on study days 13 through 17. B) The percentages of mice with normal stools in the Vehicle/C. difficile/Vanco (red
symbols, lines) and BC30/C. difficile/Vanco (green symbols/lines) treatment groups is shown in this panel. Data are shown for study days 10
through 17. On days 14 through 17, significant differences (* p < 0.05) were found in the percentages of mice with normal stools in the Vehicle/
BC30/Vanco group as compared to the Vehicle/C. difficile/Vanco group. On day 17, 88.9% of mice treated with BC30 had normal stools while this
value was 0% with vehicle treatment.
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hicle/C. difficile/No Vanco), 5.9 ± 0.6 (Vehicle/C. diffi-
cile/ Vanco) and 7.4 ± 0.4 (BC30/C. difficile/Vanco).
However, there were no statistically significant differ-
ences in stool sizes between treatment groups.BC30 treatment improved biochemical and histological
indices of recurrent CDAD in mice
Colonic myeloperoxidase (MPO) was measured with co-
lonic samples from study days 14, 16, and 17. As shown in
Figure 4, MPO (Units/2 cm colon) was significantly
reduced (p < 0.05) from 4.3 +/−0.7 (Vehicle/C. difficile/Vanco treatment) to 2.6 +/−0.2 (BC30/C. difficile/Vanco
treatment).
Representative colonic histology pictures are shown in
Figure 5. C. difficile infection, without subsequent Vanco
administration, caused altered colonic histopathology.
Specifically, some crypt damage as well as modest sub-
mucosal edema and moderate influx of inflammatory cells
into the lamina propria and sub-mucosa were evident in
the colon of this mouse (panel B). In a somewhat similar
fashion, Vehicle/C. difficile/Vanco treated mice had clear
evidence of histological pathology, including significant
sub-mucosal edema (panel C). Overall, BC30 treatment
























































































Figure 4 Colonic myeloperoxidase. Measurements of colonic
myeloperoxidase (MPO) levels for all mice are shown as Units per 2 cm
of colon. Colonic MPO was significantly (p < 0.05) reduced from 4.3 ±
0.7 (Vehicle/Vanco, red bar) to 2.6 ± 0.2 (BC30/Vanco, green bar).
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in the Vehicle/C. difficile cohort of animals (panel C). The
mean colonic histology scores were: 3.12 ± 0.35 (Vehicle/
No C. difficile), 4.49 ± 0.32 (Vehicle/C. difificile/No Vanco),
5.19 ± 0.15 (Vehicle/C. difificile/Vanco) and 4.29 ± 0.20
(BC30/C. difficile/Vanco). Of note, there was a significant
reduction (p< 0.05) in the mean histology score of BC30/C.
difficile/Vanco treated mice, as compared to Vehicle/C.
difificile/Vanco treated animals (Figure 5E).
The KC (keratinocyte derived chemokine) results (pg/2
cm colon) for all cohorts of mice were: 18.6 ± 1.2 (Ve-
hicle/No C. difficile), 26.1 ± 4.3 (Vehicle/C. difficile/No
Vanco), 20.8 ± 2.8 (Vehicle/C. difificile/Vanco) and 18.6 ±
1.9 (BC30/C. difficile/Vanco). Generally, colonic KC levels
were higher in both C. difficile/No Vanco and C. difficile/
Vanco treated mice. In contrast, the BC30/C. difficile/
Vanco treatment group had a colonic KC content that was
equivalent to mice that were not infected with C. difficile.
However, there were no statistically significant differences
between any of the treatment groups.
Some representative colonic COX-2 immunohistochem-
istry pictures are shown in Figure 6. Interestingly, immuno-
staining for COX-2 was evident primarily in the colonic
epithelial cells from a mouse that was not infected with C.
difficile (panel A). In the colon of a Vehicle/C. difficile/
Vanco treated animal there was prominent brown COX-2
staining in colonocytes, as well as infiltrating leukocytes
within the lamina propria and submucosa (panel B). Of
note, only minimal COX-2 immuno-staining (i.e., primarily
in surface colonic epithelial cells) was present within the
colon of a BC30/C. difficile/Vanco treated mouse (panel C).Discussion
Other investigators have described the recurrence of
CDAD following Vanco withdrawal in mice [10,19].
Chen et al. reported severe recurrent CDAD in mice fol-
lowing the removal of Vanco. CDAD was associated with
severe diarrhea, prominent body weight loss, marked
histological pathology, and a 58% mortality rate [10]. In
contrast, Sun and colleagues found only mild diarrhea,
transient body weight loss, and no evidence of mortality
following Vanco withdrawal in mice. It should be men-
tioned that different strains of C. difficile (VPI10463 or
UK 101) were used in the two studies, as well as some-
what different Vanco treatment regimens [10,11]. Des-
pite the fact that we used the same strain of C. difficile
(VPI10463) as Chen and colleagues, our mortality and
stool consistency results (Figure 3) are more similar to
those reported by Sun et al. [11]. Differences in these
study results may also be related to alterations in en-
dogenous bacterial flora populations within the colonies
of mice. Certain types of bacteria that predominate in
the colon (e.g., numbers of Firmicutes and Proteobac-
teria) have recently been shown by other investigators to
critically influence the severity of C. difficile induced col-
itis in mice [20].
Interestingly, our results suggested that treatment of
mice with BC30 slightly lowered the overall C. difficile
infection rate (Figure 2A), as well as the measured levels
of associated toxins in the stool (Figure 2B). However,
statistically significant differences were not found com-
pared to the corresponding cohort of vehicle treated ani-
mals. These results suggest the possibility that BC30
probiotic treatment may have lowered the actual num-
bers of C. difficile in the colonic lumen and/or mucosa.
However, more detailed follow-up studies would be
needed to critically test this possibility.
Previously, we found that pre-treatment of mice with
B30 improved the stool consistency during the primary
phase of C. difficile infection [18]. In a similar fashion,
our results show that BC30 treatment significantly
improved both the stool consistency scores and percent-
age of mice with normal stools (Figure 3) during the re-
currence phase (days 11–17) following Vanco withdrawal
in mice. Of note, mice treated with BC30 tended to have
longer and firmer stools (increased stool size) than Ve-
hicle/C. difficile treated mice. These results re-affirm the
positive effects of this probiotic on stool consistency
(Figure 3).
Other laboratories have found that toxin A secreted by
C. difficile can activate the NF-κB and AP-1 signal trans-
duction system in monocytes and colonic epithelial cells
[6,8,21]. This process leads to secretion of a key pro-
inflammatory chemokine (IL-8) and subsequent neutro-
phil influx into the colonic tissue [6,8,21]. Interestingly,
BC-30 can significantly inhibit IL-8 directed migration
Figure 5 Colonic histology. Representative histology pictures from hematoxylin and eosin (H&E) stained colonic specimens are shown at a
magnification of 200-fold. A) A relatively normal histological appearance is evident in the colon from a mouse not infected with C. difficile. B)
Evidence of crypt damage, submucosal edema and the influx of inflammatory cells in the lamina propria and sub-mucosa is present in the colon
of an animal infected with C. difficile but not treated with Vanco. C) In the colon of a mouse given C. difficile plus Vanco, there is evidence of
crypt disruption, leukocyte influx and prominent sub-mucosal edema. D) Mild pathology is observed in the colon of a BC30 treated mouse that
was also given C. difficile plus Vanco. Modest leukocyte influx is present in the lamina propria, as well as limited sub-mucosal edema, when
compared to the vehicle control (compare panels C and D). E) This panel shows a summary of the colonic histology score data. * p < 0.05 vs.
Vehicle/C. difficile/Vanco treatment group (compare red and green bars in the graph).
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results, we measured the effects of BC30 on colonic
MPO, as well the murine chemokine (KC) content in
the colons of C. difficile infected mice. Probiotic treat-
ment resulted in a significant reduction in colonic MPO(Figure 4), as well as a diminution in the KC content.
However, statistical significance was not achieved for re-
ducing this chemokine, as compared to values in vehicle
treated mice. Nevertheless, these positive effects of
BC30 on parameters associated with neutrophil influx
C BC30/C. difficile/Vanco
A Vehicle/No C. difficile B Vehicle/C. difficile/Vanco
Figure 6 Colonic COX-2 immunohistochemistry. COX-2 immunohistochemistry was performed on representative histology slides from colonic
samples of three treatment groups (panels A, B and C). As shown in panel A, Immuno-staining for COX-2 was evident primarily in the colonic
epithelial cells from a mouse that was not infected with C. difficile. In the colon of a Vehicle/C.difficile/Vanco treated animal there was prominent
brown COX-2 staining in colonocytes, as well as infiltrating leukocytes within the lamina propria and submucosa (panel B). Only minimal COX-2
immuno-staining (i.e., primarily in surface colonic epithelial cells) was present within the colon of a BC30/C. difficile/Vanco treated mouse
(panel C).
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provement in stool consistency observed in the
probiotic-treated mice.
Murine CDAD is associated with a specific colonic histo-
pathology that includes crypt damage, submucosal edema
and influx of inflammatory cells [10]. These pathological
changes were also evident during the recurrence phase in
our Vehicle/C. difficile/Vanco treated mice (panel C,
Figure 5). Interestingly, histological pathology also persisted
to some degree in the Vehicle/C. difficile/ No Vanco cohort
of mice (panel B, Figure 5), even at 8 to 11 days after the
initial infection with C. difficile. In contrast, mice treated
with BC30 showed evidence of improved colonic histopath-
ology, including decreased leukocyte influx into the colon
and diminished sub-mucosal edema (panel D, Figure 5).
Importantly, the comparisons of mean colonic histology
scores showed a statistically significant reduction in B30
treated mice compared to the corresponding vehicle cohort
of animals (Figure 5E).
Other investigators have found evidence of in vitro and
in vivo COX-2 induction in colonocytes or macrophages
following exposure to C. difficile derived toxin A [9,22].
Moreover, inducible COX-2 may contribute through pros-
taglandin formation to the alteration in stool consistency
that is a prominent feature of CDAD [10,18]. Therefore, it
is interesting that colonic COX-2 immunostaining was
dramatically diminished in the colon of BC30 treated mice
(Figure 6). It is possible that this probiotic may affect theCREB-COX-2-PGE2 pathway, which promotes fluid secre-
tion and contributes to CDAD in mice [9,10,18]. Future
studies could focus on more critically evaluating the
effects of BC30, as well as other Bacillus coagulans pro-
biotic strains, on this important pathway of CDAD.
Conclusions
BC30 limited the recurrence of CD-induced colitis fol-
lowing vancomycin withdrawal in mice. Specifically, this
probiotic significantly improved stool consistency of
mice in this recurrence model of CDAD. BC30 also sig-
nificantly attenuated histological and biochemical indices
(MPO) of infectious colitis.
Methods
Bacillus coagulans GBI-30, 6086 (GanedenBC30)
BC30 and maltodextrin were obtained from Ganeden
Biotech Inc. (Mayfield Heights, OH).
Clostridium difficile (VPI 10463)
VPI 10463 was obtained from Dr. Efi Kokkotu, (Beth
Israel Deaconess Medical Center, Boston, MA) and
ATCC (Manassas, VA).
Mice
Male C57 Bl/6 mice (≈ 9 weeks of age) were purchased
from Jackson Laboratory (Bar Harbor, ME). Mice were
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4 weeks, before use in experimental studies.
Murine Clostridium difficile-Induced colitis
The protocol for Clostridium difficile recurrence devel-
oped by Chen et al. was followed with slight modifica-
tions [10]. Briefly, an antibiotic cocktail (kanamycin (0.4
mg/mL), gentamicin (0.035 mg/mL),colistin (850 U/ml),
metronidazole (0.215 mg/mL), and vancomycin (0.045
mg/mL).was given in the drinking water to mice on
study days 0 to 3. Subsequently, clindamycin (10 mg/kg)
was administered to mice by a single i.p. injection. On
study day 6, mice were randomized to receive VPI 10463
(≈ 5 x 104 CFU) by oro-gastric gavage. A negative dis-
ease control group of animals was administered vehicle
(0.9% saline). Subsequently, on day 6, mice received ei-
ther vancomycin (50 mg/kg) or 0.9% saline (vehicle) by
oro-gastric gavage, until day 10. On study day 10, ani-
mals were randomized to receive either BC30 (2 x 109
CFU per day), or vehicle (50% maltodextrin in 0.9% sa-
line), which were dosed by oro-gastric gavage until study
day 16. Both body weight and stool consistency data
were collected daily on study days 10 through 17. Stool
samples from all mice were scored based on the
consistency of the fecal sample, as shown here: 0 = nor-
mal, 1 = loose stool, 2 = loose/some diarrhea, 3 = diar-
rhea and 4 = severe watery diarrhea [18].
Based on preliminary time course studies, mice were
euthanized on days 14, 16, or 17 (i.e., cohorts 1, 2 or 3)
in Figure 1. On these study days, we confirmed the pres-
ence of Clostridium difficile and associated toxins (A
and B) in stools with a WampoleTM CD quick check
complete kit from TECHLAB (Blacksburg, VA). Further-
more, the amount of toxins A and B in available stool
samples was determined in a semi-quantitative fashion
by use of a C. DIFFICILE TOX A/B IITM ELISA KIT
from TECHLAB (Blacksburg, VA). Also, in some mice,
stool size (length in mm) was determined with electronic
callipers from available specimens.
On these same study days (days 14, 16 or 17), mice were
euthanized; and the distal colon was collected for evaluat-
ing morphometric (colon weight), histological and bio-
chemical parameters. An overview of the study design is
shown in Figure 1. This study was repeated twice and
results were combined in the final data analyses. Since no
significant differences in measured parameters of CDAD
were found on study days 14, 16, and 17, these data were
combined for data analyses. The protocol was approved
by the Institutional Animal Care and Use Committee
(IACUC) at the Penn State College of Medicine.
Colonic histology evaluation
Using coded slides from the distal colon, four areas from
each slide were scored on a three-point severity scale:0 = Normal, 1 = Mild, 2 = Moderate, 3 = Severe, for
three different parameters. These three parameters were
epithelial damage, mucosal/submucosal edema and
leukocyte infiltration. Therefore, the total score for each
slide (i.e., mouse) was between 0 and 9 [18]. Histology
photographs (H&E staining) were captured at 200x mag-
nification using an Olympus IMT-2 microscope (Olym-
pus Corporation, Lake Success, NY) and EPIX-XCAPW
image capture software (Buffalo Grove, IL).
Colonic MPO
Colonic myeloperoxidase (MPO) was utilized as an indi-
cator of neutrophil influx into the mouse colon, as
described previously by our laboratory [18]. Results were
expressed as Units/2 cm colon.
Colonic KC (CXCL1) chemokine content
KC (keratinocyte derived chemokine) is a functionally
relevant murine chemokine [7]. The colonic KC content
was measured with an ELISA kit from R&D systems
(Minneapolis, MN). Results are expressed as pg/2 cm
colon.
COX-2 Immunohistochemistry: Mouse colon
Generally, we followed the procedures for immunohisto-
chemistry with colonic tissue samples, which have been
described previously by our laboratory [23]. For the
cyclooxygenase-2 (COX-2) primary antibody, we used a
200-fold dilution, as suggested by the manufacturer (Cell
Signaling, Danvers, MA). Representative, COX-2 immu-
nohistochemistry photographs from mouse colons were
captured at a 300x magnification, using the aforemen-
tioned Olympus IMT-2 microscope and EPIX-XCAPW
image capture software program.
Statistical analyses
All statistical analyses were performed with a GraphPad
PrismW (San Diego, CA). Differences in the percentages of
mice with normal stools, as well as percentages of mice
with C. difficile infection were determined with the Fish-
er’s exact test. Stool consistency scores were evaluated by
the Mann Whitney test. Biochemical and histological data
were evaluated using unpaired t test analyses. A p value
of < 0.05 was considered to be statistically significant for
all parameters.
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